nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.039	0.0574	CbGbCtD
Sitaxentan—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0367	0.054	CbGbCtD
Sitaxentan—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0332	0.0488	CbGbCtD
Sitaxentan—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0332	0.0488	CbGbCtD
Sitaxentan—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0324	0.0477	CbGbCtD
Sitaxentan—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0305	0.0449	CbGbCtD
Sitaxentan—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0305	0.0449	CbGbCtD
Sitaxentan—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0286	0.0421	CbGbCtD
Sitaxentan—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0278	0.0409	CbGbCtD
Sitaxentan—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0276	0.0406	CbGbCtD
Sitaxentan—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0276	0.0406	CbGbCtD
Sitaxentan—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0251	0.037	CbGbCtD
Sitaxentan—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0251	0.037	CbGbCtD
Sitaxentan—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0241	0.0355	CbGbCtD
Sitaxentan—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0238	0.035	CbGbCtD
Sitaxentan—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0231	0.034	CbGbCtD
Sitaxentan—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0209	0.0307	CbGbCtD
Sitaxentan—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0209	0.0307	CbGbCtD
Sitaxentan—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.02	0.0295	CbGbCtD
Sitaxentan—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0189	0.0277	CbGbCtD
Sitaxentan—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0177	0.0261	CbGbCtD
Sitaxentan—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0177	0.0261	CbGbCtD
Sitaxentan—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.016	0.0236	CbGbCtD
Sitaxentan—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.016	0.0236	CbGbCtD
Sitaxentan—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0138	0.0204	CbGbCtD
Sitaxentan—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0134	0.0198	CbGbCtD
Sitaxentan—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0122	0.0179	CbGbCtD
Sitaxentan—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0122	0.0179	CbGbCtD
Sitaxentan—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0117	0.0171	CbGbCtD
Sitaxentan—EDNRB—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00236	0.0476	CbGpPWpGaD
Sitaxentan—EDNRB—retina—acquired immunodeficiency syndrome	0.00227	0.118	CbGeAlD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00183	0.037	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00169	0.0341	CbGpPWpGaD
Sitaxentan—EDNRB—spinal cord—acquired immunodeficiency syndrome	0.00146	0.0763	CbGeAlD
Sitaxentan—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00146	0.0762	CbGeAlD
Sitaxentan—EDNRA—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.00143	0.0289	CbGpPWpGaD
Sitaxentan—EDNRB—vagina—acquired immunodeficiency syndrome	0.00141	0.0734	CbGeAlD
Sitaxentan—EDNRB—lung—acquired immunodeficiency syndrome	0.00133	0.0694	CbGeAlD
Sitaxentan—EDNRB—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00132	0.0266	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00131	0.0265	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00124	0.025	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00123	0.0248	CbGpPWpGaD
Sitaxentan—EDNRA—vagina—acquired immunodeficiency syndrome	0.00116	0.0607	CbGeAlD
Sitaxentan—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00113	0.0591	CbGeAlD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00111	0.0224	CbGpPWpGaD
Sitaxentan—EDNRA—lung—acquired immunodeficiency syndrome	0.0011	0.0574	CbGeAlD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.001	0.0203	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000944	0.019	CbGpPWpGaD
Sitaxentan—EDNRB—brain—acquired immunodeficiency syndrome	0.000943	0.0491	CbGeAlD
Sitaxentan—EDNRB—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000936	0.0189	CbGpPWpGaD
Sitaxentan—EDNRB—lymph node—acquired immunodeficiency syndrome	0.000911	0.0475	CbGeAlD
Sitaxentan—EDNRA—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000887	0.0179	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000879	0.0177	CbGpPWpGaD
Sitaxentan—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000865	0.0451	CbGeAlD
Sitaxentan—EDNRB—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00085	0.0171	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000794	0.016	CbGpPWpGaD
Sitaxentan—EDNRA—brain—acquired immunodeficiency syndrome	0.000779	0.0406	CbGeAlD
Sitaxentan—EDNRA—lymph node—acquired immunodeficiency syndrome	0.000753	0.0392	CbGeAlD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000745	0.015	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000718	0.0145	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000686	0.0138	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000673	0.0136	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00067	0.0135	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00062	0.0125	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000608	0.0123	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000583	0.0118	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000583	0.0118	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000567	0.0114	CbGpPWpGaD
Sitaxentan—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000563	0.0293	CbGeAlD
Sitaxentan—CYP2C19—blood—acquired immunodeficiency syndrome	0.000536	0.0279	CbGeAlD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000533	0.0108	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000515	0.0104	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000513	0.0103	CbGpPWpGaD
Sitaxentan—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000497	0.0259	CbGeAlD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000491	0.0099	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000486	0.0098	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000482	0.00972	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00048	0.00969	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00046	0.00928	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000456	0.00921	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000444	0.00895	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000444	0.00895	CbGpPWpGaD
Sitaxentan—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000436	0.0227	CbGeAlD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000417	0.00842	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000417	0.00842	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000416	0.00839	CbGpPWpGaD
Sitaxentan—CYP2C9—blood—acquired immunodeficiency syndrome	0.000416	0.0217	CbGeAlD
Sitaxentan—EDNRA—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000406	0.00819	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.0004	0.00806	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000391	0.00789	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000391	0.00789	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000367	0.0074	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00035	0.00707	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000347	0.00701	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000344	0.00693	CbGpPWpGaD
Sitaxentan—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000333	0.0173	CbGeAlD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000329	0.00664	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000327	0.00659	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000317	0.0064	CbGpPWpGaD
Sitaxentan—CYP3A4—blood—acquired immunodeficiency syndrome	0.000317	0.0165	CbGeAlD
Sitaxentan—EDNRB—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000317	0.00639	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000313	0.00631	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000298	0.00601	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000298	0.00601	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000298	0.00601	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000298	0.006	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000291	0.00587	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000286	0.00577	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000284	0.00572	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00028	0.00565	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00028	0.00565	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000268	0.00541	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000263	0.00531	CbGpPWpGaD
Sitaxentan—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000257	0.0134	CbGeAlD
Sitaxentan—EDNRA—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000251	0.00506	CbGpPWpGaD
Sitaxentan—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000248	0.0129	CbGeAlD
Sitaxentan—EDNRA—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000227	0.00457	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000227	0.00457	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000224	0.00452	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000213	0.0043	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000213	0.0043	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000213	0.0043	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000208	0.0042	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000204	0.00412	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000203	0.0041	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000192	0.00387	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000188	0.0038	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00018	0.00363	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000179	0.00361	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000172	0.00347	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000172	0.00347	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000168	0.0034	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000168	0.0034	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000163	0.00328	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000162	0.00327	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000155	0.00314	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000153	0.00308	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000153	0.00308	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000146	0.00295	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000129	0.0026	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000128	0.00258	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000128	0.00258	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000126	0.00254	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000123	0.00248	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000123	0.00248	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000123	0.00248	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00012	0.00243	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00012	0.00243	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000116	0.00235	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000116	0.00235	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000115	0.00233	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000115	0.00231	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000111	0.00224	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000109	0.00221	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000109	0.00221	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000106	0.00214	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000105	0.00211	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000103	0.000412	CcSEcCtD
Sitaxentan—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000411	CcSEcCtD
Sitaxentan—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.00041	CcSEcCtD
Sitaxentan—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.00041	CcSEcCtD
Sitaxentan—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000102	0.000408	CcSEcCtD
Sitaxentan—Discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000406	CcSEcCtD
Sitaxentan—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000102	0.000405	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000102	0.000405	CcSEcCtD
Sitaxentan—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000102	0.000404	CcSEcCtD
Sitaxentan—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000102	0.000404	CcSEcCtD
Sitaxentan—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000101	0.000403	CcSEcCtD
Sitaxentan—Malaise—Ritonavir—acquired immunodeficiency syndrome	0.000101	0.000403	CcSEcCtD
Sitaxentan—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.000403	CcSEcCtD
Sitaxentan—Tension—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000402	CcSEcCtD
Sitaxentan—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.000402	CcSEcCtD
Sitaxentan—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000101	0.000402	CcSEcCtD
Sitaxentan—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000101	0.000401	CcSEcCtD
Sitaxentan—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000101	0.000401	CcSEcCtD
Sitaxentan—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000101	0.000401	CcSEcCtD
Sitaxentan—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000101	0.000401	CcSEcCtD
Sitaxentan—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000101	0.0004	CcSEcCtD
Sitaxentan—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.0001	0.0004	CcSEcCtD
Sitaxentan—Ill-defined disorder—Saquinavir—acquired immunodeficiency syndrome	0.0001	0.000399	CcSEcCtD
Sitaxentan—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.0001	0.000399	CcSEcCtD
Sitaxentan—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.0001	0.000398	CcSEcCtD
Sitaxentan—Confusional state—Delavirdine—acquired immunodeficiency syndrome	9.99e-05	0.000397	CcSEcCtD
Sitaxentan—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	9.99e-05	0.000397	CcSEcCtD
Sitaxentan—Anaemia—Saquinavir—acquired immunodeficiency syndrome	9.98e-05	0.000397	CcSEcCtD
Sitaxentan—Vomiting—Didanosine—acquired immunodeficiency syndrome	9.93e-05	0.000395	CcSEcCtD
Sitaxentan—Agitation—Saquinavir—acquired immunodeficiency syndrome	9.93e-05	0.000395	CcSEcCtD
Sitaxentan—Insomnia—Indinavir—acquired immunodeficiency syndrome	9.91e-05	0.000394	CcSEcCtD
Sitaxentan—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	9.91e-05	0.000394	CcSEcCtD
Sitaxentan—Oedema—Delavirdine—acquired immunodeficiency syndrome	9.9e-05	0.000394	CcSEcCtD
Sitaxentan—Anorexia—Efavirenz—acquired immunodeficiency syndrome	9.87e-05	0.000393	CcSEcCtD
Sitaxentan—Rash—Didanosine—acquired immunodeficiency syndrome	9.84e-05	0.000392	CcSEcCtD
Sitaxentan—Infection—Delavirdine—acquired immunodeficiency syndrome	9.84e-05	0.000392	CcSEcCtD
Sitaxentan—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	9.84e-05	0.000392	CcSEcCtD
Sitaxentan—Dermatitis—Didanosine—acquired immunodeficiency syndrome	9.83e-05	0.000391	CcSEcCtD
Sitaxentan—Headache—Didanosine—acquired immunodeficiency syndrome	9.78e-05	0.000389	CcSEcCtD
Sitaxentan—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	9.75e-05	0.000388	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	9.75e-05	0.00197	CbGpPWpGaD
Sitaxentan—Malaise—Saquinavir—acquired immunodeficiency syndrome	9.74e-05	0.000388	CcSEcCtD
Sitaxentan—Somnolence—Indinavir—acquired immunodeficiency syndrome	9.74e-05	0.000388	CcSEcCtD
Sitaxentan—Asthenia—Stavudine—acquired immunodeficiency syndrome	9.72e-05	0.000387	CcSEcCtD
Sitaxentan—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	9.71e-05	0.000386	CcSEcCtD
Sitaxentan—Vertigo—Saquinavir—acquired immunodeficiency syndrome	9.7e-05	0.000386	CcSEcCtD
Sitaxentan—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	9.7e-05	0.000386	CcSEcCtD
Sitaxentan—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	9.67e-05	0.000385	CcSEcCtD
Sitaxentan—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	9.67e-05	0.000385	CcSEcCtD
Sitaxentan—Tremor—Lamivudine—acquired immunodeficiency syndrome	9.65e-05	0.000384	CcSEcCtD
Sitaxentan—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	9.64e-05	0.000384	CcSEcCtD
Sitaxentan—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	9.62e-05	0.000383	CcSEcCtD
Sitaxentan—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	9.6e-05	0.000382	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.6e-05	0.00194	CbGpPWpGaD
Sitaxentan—Asthenia—Abacavir—acquired immunodeficiency syndrome	9.58e-05	0.000381	CcSEcCtD
Sitaxentan—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	9.56e-05	0.000381	CcSEcCtD
Sitaxentan—Chest pain—Ritonavir—acquired immunodeficiency syndrome	9.55e-05	0.00038	CcSEcCtD
Sitaxentan—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	9.52e-05	0.000379	CcSEcCtD
Sitaxentan—Anaemia—Lamivudine—acquired immunodeficiency syndrome	9.52e-05	0.000379	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	9.49e-05	0.000378	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	9.46e-05	0.000376	CcSEcCtD
Sitaxentan—Fatigue—Indinavir—acquired immunodeficiency syndrome	9.45e-05	0.000376	CcSEcCtD
Sitaxentan—Anorexia—Delavirdine—acquired immunodeficiency syndrome	9.44e-05	0.000376	CcSEcCtD
Sitaxentan—Discomfort—Ritonavir—acquired immunodeficiency syndrome	9.44e-05	0.000376	CcSEcCtD
Sitaxentan—Pain—Indinavir—acquired immunodeficiency syndrome	9.37e-05	0.000373	CcSEcCtD
Sitaxentan—Constipation—Indinavir—acquired immunodeficiency syndrome	9.37e-05	0.000373	CcSEcCtD
Sitaxentan—Insomnia—Efavirenz—acquired immunodeficiency syndrome	9.36e-05	0.000373	CcSEcCtD
Sitaxentan—Urticaria—Zidovudine—acquired immunodeficiency syndrome	9.36e-05	0.000373	CcSEcCtD
Sitaxentan—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	9.34e-05	0.000372	CcSEcCtD
Sitaxentan—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	9.31e-05	0.000371	CcSEcCtD
Sitaxentan—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	9.3e-05	0.00037	CcSEcCtD
Sitaxentan—Malaise—Lamivudine—acquired immunodeficiency syndrome	9.29e-05	0.00037	CcSEcCtD
Sitaxentan—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	9.27e-05	0.000369	CcSEcCtD
Sitaxentan—Nausea—Didanosine—acquired immunodeficiency syndrome	9.27e-05	0.000369	CcSEcCtD
Sitaxentan—Vertigo—Lamivudine—acquired immunodeficiency syndrome	9.26e-05	0.000368	CcSEcCtD
Sitaxentan—Hypotension—Delavirdine—acquired immunodeficiency syndrome	9.25e-05	0.000368	CcSEcCtD
Sitaxentan—Confusional state—Ritonavir—acquired immunodeficiency syndrome	9.23e-05	0.000368	CcSEcCtD
Sitaxentan—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	9.22e-05	0.000367	CcSEcCtD
Sitaxentan—Somnolence—Efavirenz—acquired immunodeficiency syndrome	9.2e-05	0.000366	CcSEcCtD
Sitaxentan—Chest pain—Saquinavir—acquired immunodeficiency syndrome	9.2e-05	0.000366	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.16e-05	0.00185	CbGpPWpGaD
Sitaxentan—Oedema—Ritonavir—acquired immunodeficiency syndrome	9.16e-05	0.000365	CcSEcCtD
Sitaxentan—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	9.14e-05	0.000364	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	9.13e-05	0.000363	CcSEcCtD
Sitaxentan—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	9.11e-05	0.000363	CcSEcCtD
Sitaxentan—Discomfort—Saquinavir—acquired immunodeficiency syndrome	9.08e-05	0.000362	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.03e-05	0.00182	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.03e-05	0.00182	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	9.03e-05	0.000359	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.03e-05	0.00182	CbGpPWpGaD
Sitaxentan—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	9e-05	0.000358	CcSEcCtD
Sitaxentan—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	8.99e-05	0.000358	CcSEcCtD
Sitaxentan—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	8.99e-05	0.000358	CcSEcCtD
Sitaxentan—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	8.98e-05	0.000358	CcSEcCtD
Sitaxentan—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	8.97e-05	0.000357	CcSEcCtD
Sitaxentan—Dizziness—Stavudine—acquired immunodeficiency syndrome	8.96e-05	0.000357	CcSEcCtD
Sitaxentan—Insomnia—Delavirdine—acquired immunodeficiency syndrome	8.96e-05	0.000357	CcSEcCtD
Sitaxentan—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	8.94e-05	0.000356	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	8.94e-05	0.000356	CcSEcCtD
Sitaxentan—Vomiting—Nevirapine—acquired immunodeficiency syndrome	8.92e-05	0.000355	CcSEcCtD
Sitaxentan—Fatigue—Efavirenz—acquired immunodeficiency syndrome	8.92e-05	0.000355	CcSEcCtD
Sitaxentan—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	8.9e-05	0.000354	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	8.89e-05	0.00179	CbGpPWpGaD
Sitaxentan—Confusional state—Saquinavir—acquired immunodeficiency syndrome	8.89e-05	0.000354	CcSEcCtD
Sitaxentan—Pain—Efavirenz—acquired immunodeficiency syndrome	8.85e-05	0.000352	CcSEcCtD
Sitaxentan—Constipation—Efavirenz—acquired immunodeficiency syndrome	8.85e-05	0.000352	CcSEcCtD
Sitaxentan—Rash—Nevirapine—acquired immunodeficiency syndrome	8.85e-05	0.000352	CcSEcCtD
Sitaxentan—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	8.84e-05	0.000352	CcSEcCtD
Sitaxentan—Dizziness—Abacavir—acquired immunodeficiency syndrome	8.83e-05	0.000351	CcSEcCtD
Sitaxentan—Oedema—Saquinavir—acquired immunodeficiency syndrome	8.81e-05	0.000351	CcSEcCtD
Sitaxentan—Somnolence—Delavirdine—acquired immunodeficiency syndrome	8.8e-05	0.00035	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	8.8e-05	0.00178	CbGpPWpGaD
Sitaxentan—Headache—Nevirapine—acquired immunodeficiency syndrome	8.79e-05	0.00035	CcSEcCtD
Sitaxentan—Chest pain—Lamivudine—acquired immunodeficiency syndrome	8.77e-05	0.000349	CcSEcCtD
Sitaxentan—Infection—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000349	CcSEcCtD
Sitaxentan—Anorexia—Ritonavir—acquired immunodeficiency syndrome	8.73e-05	0.000347	CcSEcCtD
Sitaxentan—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	8.72e-05	0.000347	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	8.71e-05	0.000347	CcSEcCtD
Sitaxentan—Urticaria—Indinavir—acquired immunodeficiency syndrome	8.7e-05	0.000346	CcSEcCtD
Sitaxentan—Discomfort—Lamivudine—acquired immunodeficiency syndrome	8.67e-05	0.000345	CcSEcCtD
Sitaxentan—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	8.66e-05	0.000345	CcSEcCtD
Sitaxentan—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	8.64e-05	0.000344	CcSEcCtD
Sitaxentan—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	8.64e-05	0.000344	CcSEcCtD
Sitaxentan—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	8.63e-05	0.000344	CcSEcCtD
Sitaxentan—Vomiting—Stavudine—acquired immunodeficiency syndrome	8.62e-05	0.000343	CcSEcCtD
Sitaxentan—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	8.61e-05	0.000343	CcSEcCtD
Sitaxentan—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	8.58e-05	0.000341	CcSEcCtD
Sitaxentan—Rash—Nelfinavir—acquired immunodeficiency syndrome	8.57e-05	0.000341	CcSEcCtD
Sitaxentan—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	8.56e-05	0.000341	CcSEcCtD
Sitaxentan—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	8.56e-05	0.000341	CcSEcCtD
Sitaxentan—Hypotension—Ritonavir—acquired immunodeficiency syndrome	8.56e-05	0.000341	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	8.55e-05	0.00034	CcSEcCtD
Sitaxentan—Rash—Stavudine—acquired immunodeficiency syndrome	8.55e-05	0.00034	CcSEcCtD
Sitaxentan—Fatigue—Delavirdine—acquired immunodeficiency syndrome	8.54e-05	0.00034	CcSEcCtD
Sitaxentan—Dermatitis—Stavudine—acquired immunodeficiency syndrome	8.54e-05	0.00034	CcSEcCtD
Sitaxentan—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	8.53e-05	0.00034	CcSEcCtD
Sitaxentan—Headache—Nelfinavir—acquired immunodeficiency syndrome	8.52e-05	0.000339	CcSEcCtD
Sitaxentan—Headache—Stavudine—acquired immunodeficiency syndrome	8.49e-05	0.000338	CcSEcCtD
Sitaxentan—Vomiting—Abacavir—acquired immunodeficiency syndrome	8.49e-05	0.000338	CcSEcCtD
Sitaxentan—Confusional state—Lamivudine—acquired immunodeficiency syndrome	8.48e-05	0.000338	CcSEcCtD
Sitaxentan—Pain—Delavirdine—acquired immunodeficiency syndrome	8.47e-05	0.000337	CcSEcCtD
Sitaxentan—Constipation—Delavirdine—acquired immunodeficiency syndrome	8.47e-05	0.000337	CcSEcCtD
Sitaxentan—Asthenia—Zidovudine—acquired immunodeficiency syndrome	8.45e-05	0.000336	CcSEcCtD
Sitaxentan—Rash—Abacavir—acquired immunodeficiency syndrome	8.42e-05	0.000335	CcSEcCtD
Sitaxentan—Dermatitis—Abacavir—acquired immunodeficiency syndrome	8.41e-05	0.000335	CcSEcCtD
Sitaxentan—Oedema—Lamivudine—acquired immunodeficiency syndrome	8.41e-05	0.000335	CcSEcCtD
Sitaxentan—Anorexia—Saquinavir—acquired immunodeficiency syndrome	8.4e-05	0.000334	CcSEcCtD
Sitaxentan—Headache—Abacavir—acquired immunodeficiency syndrome	8.36e-05	0.000333	CcSEcCtD
Sitaxentan—Infection—Lamivudine—acquired immunodeficiency syndrome	8.35e-05	0.000333	CcSEcCtD
Sitaxentan—Nausea—Nevirapine—acquired immunodeficiency syndrome	8.34e-05	0.000332	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.32e-05	0.00168	CbGpPWpGaD
Sitaxentan—Insomnia—Ritonavir—acquired immunodeficiency syndrome	8.28e-05	0.00033	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.26e-05	0.00167	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	8.25e-05	0.000328	CcSEcCtD
Sitaxentan—Hypotension—Saquinavir—acquired immunodeficiency syndrome	8.24e-05	0.000328	CcSEcCtD
Sitaxentan—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	8.23e-05	0.000328	CcSEcCtD
Sitaxentan—Urticaria—Efavirenz—acquired immunodeficiency syndrome	8.22e-05	0.000327	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.2e-05	0.00165	CbGpPWpGaD
Sitaxentan—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	8.18e-05	0.000326	CcSEcCtD
Sitaxentan—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	8.17e-05	0.000325	CcSEcCtD
Sitaxentan—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	8.16e-05	0.000325	CcSEcCtD
Sitaxentan—Somnolence—Ritonavir—acquired immunodeficiency syndrome	8.14e-05	0.000324	CcSEcCtD
Sitaxentan—Nausea—Nelfinavir—acquired immunodeficiency syndrome	8.07e-05	0.000321	CcSEcCtD
Sitaxentan—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	8.07e-05	0.000321	CcSEcCtD
Sitaxentan—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	8.06e-05	0.000321	CcSEcCtD
Sitaxentan—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	8.06e-05	0.000321	CcSEcCtD
Sitaxentan—Nausea—Stavudine—acquired immunodeficiency syndrome	8.05e-05	0.00032	CcSEcCtD
Sitaxentan—Anorexia—Lamivudine—acquired immunodeficiency syndrome	8.02e-05	0.000319	CcSEcCtD
Sitaxentan—Insomnia—Saquinavir—acquired immunodeficiency syndrome	7.97e-05	0.000317	CcSEcCtD
Sitaxentan—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	7.96e-05	0.000317	CcSEcCtD
Sitaxentan—Nausea—Abacavir—acquired immunodeficiency syndrome	7.93e-05	0.000316	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	7.91e-05	0.000315	CcSEcCtD
Sitaxentan—Fatigue—Ritonavir—acquired immunodeficiency syndrome	7.9e-05	0.000314	CcSEcCtD
Sitaxentan—Urticaria—Delavirdine—acquired immunodeficiency syndrome	7.87e-05	0.000313	CcSEcCtD
Sitaxentan—Asthenia—Indinavir—acquired immunodeficiency syndrome	7.86e-05	0.000313	CcSEcCtD
Sitaxentan—Hypotension—Lamivudine—acquired immunodeficiency syndrome	7.86e-05	0.000313	CcSEcCtD
Sitaxentan—Somnolence—Saquinavir—acquired immunodeficiency syndrome	7.84e-05	0.000312	CcSEcCtD
Sitaxentan—Constipation—Ritonavir—acquired immunodeficiency syndrome	7.83e-05	0.000312	CcSEcCtD
Sitaxentan—Pain—Ritonavir—acquired immunodeficiency syndrome	7.83e-05	0.000312	CcSEcCtD
Sitaxentan—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	7.83e-05	0.000312	CcSEcCtD
Sitaxentan—Dizziness—Zidovudine—acquired immunodeficiency syndrome	7.79e-05	0.00031	CcSEcCtD
Sitaxentan—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	7.76e-05	0.000309	CcSEcCtD
Sitaxentan—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	7.66e-05	0.000305	CcSEcCtD
Sitaxentan—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	7.63e-05	0.000304	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	7.61e-05	0.000303	CcSEcCtD
Sitaxentan—Insomnia—Lamivudine—acquired immunodeficiency syndrome	7.61e-05	0.000303	CcSEcCtD
Sitaxentan—Fatigue—Saquinavir—acquired immunodeficiency syndrome	7.6e-05	0.000303	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.6e-05	0.00153	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	7.55e-05	0.0003	CcSEcCtD
Sitaxentan—Pain—Saquinavir—acquired immunodeficiency syndrome	7.54e-05	0.0003	CcSEcCtD
Sitaxentan—Constipation—Saquinavir—acquired immunodeficiency syndrome	7.54e-05	0.0003	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.5e-05	0.00151	CbGpPWpGaD
Sitaxentan—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	7.5e-05	0.000298	CcSEcCtD
Sitaxentan—Vomiting—Zidovudine—acquired immunodeficiency syndrome	7.49e-05	0.000298	CcSEcCtD
Sitaxentan—Somnolence—Lamivudine—acquired immunodeficiency syndrome	7.48e-05	0.000298	CcSEcCtD
Sitaxentan—Rash—Zidovudine—acquired immunodeficiency syndrome	7.43e-05	0.000296	CcSEcCtD
Sitaxentan—Asthenia—Efavirenz—acquired immunodeficiency syndrome	7.43e-05	0.000296	CcSEcCtD
Sitaxentan—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	7.42e-05	0.000295	CcSEcCtD
Sitaxentan—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	7.4e-05	0.000295	CcSEcCtD
Sitaxentan—Headache—Zidovudine—acquired immunodeficiency syndrome	7.38e-05	0.000294	CcSEcCtD
Sitaxentan—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	7.31e-05	0.000291	CcSEcCtD
Sitaxentan—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	7.3e-05	0.00029	CcSEcCtD
Sitaxentan—Urticaria—Ritonavir—acquired immunodeficiency syndrome	7.28e-05	0.00029	CcSEcCtD
Sitaxentan—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	7.26e-05	0.000289	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	7.26e-05	0.000289	CcSEcCtD
Sitaxentan—Fatigue—Lamivudine—acquired immunodeficiency syndrome	7.25e-05	0.000289	CcSEcCtD
Sitaxentan—Dizziness—Indinavir—acquired immunodeficiency syndrome	7.24e-05	0.000288	CcSEcCtD
Sitaxentan—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	7.24e-05	0.000288	CcSEcCtD
Sitaxentan—Pain—Lamivudine—acquired immunodeficiency syndrome	7.19e-05	0.000286	CcSEcCtD
Sitaxentan—Constipation—Lamivudine—acquired immunodeficiency syndrome	7.19e-05	0.000286	CcSEcCtD
Sitaxentan—Asthenia—Delavirdine—acquired immunodeficiency syndrome	7.11e-05	0.000283	CcSEcCtD
Sitaxentan—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	7.08e-05	0.000282	CcSEcCtD
Sitaxentan—Urticaria—Saquinavir—acquired immunodeficiency syndrome	7e-05	0.000279	CcSEcCtD
Sitaxentan—Nausea—Zidovudine—acquired immunodeficiency syndrome	7e-05	0.000279	CcSEcCtD
Sitaxentan—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.97e-05	0.000277	CcSEcCtD
Sitaxentan—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.97e-05	0.000277	CcSEcCtD
Sitaxentan—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	6.93e-05	0.000276	CcSEcCtD
Sitaxentan—Rash—Indinavir—acquired immunodeficiency syndrome	6.91e-05	0.000275	CcSEcCtD
Sitaxentan—Dermatitis—Indinavir—acquired immunodeficiency syndrome	6.9e-05	0.000275	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.87e-05	0.00139	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.87e-05	0.00139	CbGpPWpGaD
Sitaxentan—Headache—Indinavir—acquired immunodeficiency syndrome	6.86e-05	0.000273	CcSEcCtD
Sitaxentan—Dizziness—Efavirenz—acquired immunodeficiency syndrome	6.84e-05	0.000272	CcSEcCtD
Sitaxentan—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	6.78e-05	0.00027	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.77e-05	0.00137	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	6.75e-05	0.000269	CcSEcCtD
Sitaxentan—Urticaria—Lamivudine—acquired immunodeficiency syndrome	6.68e-05	0.000266	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.66e-05	0.00134	CbGpPWpGaD
Sitaxentan—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	6.65e-05	0.000265	CcSEcCtD
Sitaxentan—Vomiting—Efavirenz—acquired immunodeficiency syndrome	6.58e-05	0.000262	CcSEcCtD
Sitaxentan—Asthenia—Ritonavir—acquired immunodeficiency syndrome	6.57e-05	0.000262	CcSEcCtD
Sitaxentan—Dizziness—Delavirdine—acquired immunodeficiency syndrome	6.55e-05	0.000261	CcSEcCtD
Sitaxentan—Rash—Efavirenz—acquired immunodeficiency syndrome	6.53e-05	0.00026	CcSEcCtD
Sitaxentan—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	6.52e-05	0.00026	CcSEcCtD
Sitaxentan—Nausea—Indinavir—acquired immunodeficiency syndrome	6.51e-05	0.000259	CcSEcCtD
Sitaxentan—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	6.49e-05	0.000259	CcSEcCtD
Sitaxentan—Headache—Efavirenz—acquired immunodeficiency syndrome	6.48e-05	0.000258	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.46e-05	0.0013	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.46e-05	0.0013	CbGpPWpGaD
Sitaxentan—Asthenia—Saquinavir—acquired immunodeficiency syndrome	6.32e-05	0.000252	CcSEcCtD
Sitaxentan—Vomiting—Delavirdine—acquired immunodeficiency syndrome	6.3e-05	0.000251	CcSEcCtD
Sitaxentan—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	6.27e-05	0.000249	CcSEcCtD
Sitaxentan—Rash—Delavirdine—acquired immunodeficiency syndrome	6.24e-05	0.000249	CcSEcCtD
Sitaxentan—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	6.24e-05	0.000248	CcSEcCtD
Sitaxentan—Headache—Delavirdine—acquired immunodeficiency syndrome	6.2e-05	0.000247	CcSEcCtD
Sitaxentan—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	6.2e-05	0.000247	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.19e-05	0.00125	CbGpPWpGaD
Sitaxentan—Nausea—Efavirenz—acquired immunodeficiency syndrome	6.15e-05	0.000245	CcSEcCtD
Sitaxentan—Dizziness—Ritonavir—acquired immunodeficiency syndrome	6.06e-05	0.000241	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.05e-05	0.00122	CbGpPWpGaD
Sitaxentan—Asthenia—Lamivudine—acquired immunodeficiency syndrome	6.03e-05	0.00024	CcSEcCtD
Sitaxentan—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	6.03e-05	0.00024	CcSEcCtD
Sitaxentan—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.88e-05	0.000234	CcSEcCtD
Sitaxentan—Dizziness—Saquinavir—acquired immunodeficiency syndrome	5.83e-05	0.000232	CcSEcCtD
Sitaxentan—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.82e-05	0.000232	CcSEcCtD
Sitaxentan—Rash—Ritonavir—acquired immunodeficiency syndrome	5.77e-05	0.00023	CcSEcCtD
Sitaxentan—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.77e-05	0.00023	CcSEcCtD
Sitaxentan—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.75e-05	0.000229	CcSEcCtD
Sitaxentan—Headache—Ritonavir—acquired immunodeficiency syndrome	5.74e-05	0.000228	CcSEcCtD
Sitaxentan—Vomiting—Saquinavir—acquired immunodeficiency syndrome	5.6e-05	0.000223	CcSEcCtD
Sitaxentan—Dizziness—Lamivudine—acquired immunodeficiency syndrome	5.56e-05	0.000221	CcSEcCtD
Sitaxentan—Rash—Saquinavir—acquired immunodeficiency syndrome	5.56e-05	0.000221	CcSEcCtD
Sitaxentan—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	5.55e-05	0.000221	CcSEcCtD
Sitaxentan—Headache—Saquinavir—acquired immunodeficiency syndrome	5.52e-05	0.00022	CcSEcCtD
Sitaxentan—Nausea—Ritonavir—acquired immunodeficiency syndrome	5.44e-05	0.000217	CcSEcCtD
Sitaxentan—Vomiting—Lamivudine—acquired immunodeficiency syndrome	5.35e-05	0.000213	CcSEcCtD
Sitaxentan—Rash—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.000211	CcSEcCtD
Sitaxentan—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.000211	CcSEcCtD
Sitaxentan—Headache—Lamivudine—acquired immunodeficiency syndrome	5.27e-05	0.00021	CcSEcCtD
Sitaxentan—Nausea—Saquinavir—acquired immunodeficiency syndrome	5.24e-05	0.000208	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	5.11e-05	0.00103	CbGpPWpGaD
Sitaxentan—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.99e-05	0.000199	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.92e-05	0.000992	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.84e-05	0.000977	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.77e-05	0.000962	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	4.66e-05	0.000939	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.43e-05	0.000894	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	4.34e-05	0.000876	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.33e-05	0.000874	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	3.96e-05	0.000799	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.58e-05	0.000721	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.56e-05	0.000718	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	3.07e-05	0.00062	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	2.61e-05	0.000527	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.56e-05	0.000516	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.55e-05	0.000514	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.1e-05	0.000424	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2e-05	0.000403	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.82e-05	0.000368	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.5e-05	0.000303	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	8.9e-06	0.00018	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	8.12e-06	0.000164	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	5.35e-06	0.000108	CbGpPWpGaD
